Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin αIIbβ3 (GPIIb/IIIa) antagonists, c7E3 and DMP728

Thrombosis Research

Volumn 88, Issue 2, 1997, Pages 137-146

  Tsao, Peter W ^a   Forsythe, Mark S ^a   Mousa, Shaker A ^a  

^a DUPONT COMPANY   (United States)

Author keywords

P selectin; Platelet secretion; Type 1 plasminogen activator inhibitor; IIb 3 integrin; V 3 integrin; Thromboglobulin

Indexed keywords

HERBIMYCIN; PADGEM PROTEIN; STAUROSPORINE;

ARTICLE; CELLULAR DISTRIBUTION; DISEASE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBUS;

ANTIBODIES, MONOCLONAL; BENZOQUINONES; BETA-THROMBOGLOBULIN; ENZYME INHIBITORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LACTAMS, MACROCYCLIC; MESYLATES; OLIGOPEPTIDES; P-SELECTIN; PEPTIDES, CYCLIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; QUINONES; STAUROSPORINE;

EID: 0030725363     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0049-3848(97)00225-9     Document Type: Article

References (24)

1. COLLER, B.S. Antiplatelet agents in the prevention and therapy of thrombosis. Ann Rev Med 43, 17 180, 1992.
2. PHILLIPS, D.R., CHARO, I.F., SCARBOROUGH, R.M. GPIIb-IIIa: The responsive integrin. Cell 65, 359-362, 1991.
3. SEISS, W. Molecular mechanisms of platelet activation. Physiol Rev 69, 58-178 1989.
4. RENDU, F., ELDOR, A., GRELAC, F., BACHELOT, C., GAZIT, A., GILON, C., LEVY-TOLEDANO, S., LEVITZKI, A. Inhibition of platelet activation by tyrosine kinase inhibitors. Biochem Pharmacol 44, 881-888, 1992.
5. WATSON, S.P., MCNALLY, J., SHIPMAN, L.J., GODFREY, P.P. The action of the protein kinase C inhibitor, staurosporine, on human platelets. Biochem J 249, 345-350, 1988.
6. COLLER, B., ANDERSON, K., WEISMAN, H.F. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 74, 302-308, 1995.
7. MOUSA, S.A., BOZARTH, J.M., FORSYTHE, M.S., LORELLI, W., THOOLEN, M.J., RAMACHANDRAN, N., JACKSON, S., DEGRADO, W., REILLY, T.M. Anti-platelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Cardiology 83, 374-382, 1993.
8. MOUSA, S.A., BOZARTH, J.M., FORSYTHE, M.S., JACKSON, S.A., LEAMY, A., DIEMER, M.J., KAPIL, R.P., KNABB, R.M., MAYO, M.C., PIERCE, S.K., DEGRADO, W., THOOLEN, M.J., REILLY, T.M. Antiplatelet and antithrombotic efficacy of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 89, 3-12, 1994.
9. TORR-BROWN, S.R., SOBEL, B.E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 72, 413-421, 1993.
10. PALABRICA, T., LOBB, R., FURIE, B.C., WAGNER, D.D., SAJER, S., FURIE, B. Leukocyte accumulation which promotes fibrin deposition is mediated in vivo by P-selectin (CD62) on adherent platelets. Nature 359, 848-851, 1992.
11. REILLY, T.M., LORELLI, W.F., PIERCE, S.K., SPITZ, S.M., WALTON H.L. Monoclonal antibodies against a recombinant form of plasminogen activator inhibitor-1: Effect on tissue plasminogen activator neutralizing and vitronectin binding properties. Fibrinolysis 7, 373-378, 1993.
12. BERMAN, C.L., YEO, E.L., WENCEL-DRAKE, J.D., FURIE, B.C., GINSBERG, M.H., FURIE, B. A. Platelet alpha granule membrane protein that is associated with the plasma membrane after activation. J Clin Invest 78, 130-136, 1986.
13. TSAO, P.W., BOZARTH, J.M., JACKSON, S.A., FORSYTHE, M.S., FLINT, S.K., MOUSA, S.A. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic arg-gly-asp peptide. Thromb Res 77, 543-556, 1995.
14. MOUSA, S.A., BOZARTH, J., FORSYTHE, M., TSAO, P., PEASE, L., REILLY, T.M. Role of platelet GPIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitor type-1. Life Sci 54, 1155-1162, 1994.
15. KERRY, P.J., CURTIS, A.D. Standardization of β-thromboglobulin (β-TG) and platelet factor 4 (PF4): a collaborative study to establish international standards for β-TG and PF4. Thromb. Haemostasis 53, 51-55, 1985.
16. TAMAOKI, T., NOMOTO, H., TAKAHASHI, I., KATO, Y., MORIMOTO, M., TOMITA, F. Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochem Biophys Res Commun 135, 397-402, 1986.
17. UEHARA, Y., FUKAZAWA, H. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. Methods Enzymol 201, 370-379, 1991.
18. BOOTH, N.A., SIMPSON, A.J., CROLL, A., BENNETT, B., Macgregor, I.R. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 70, 327-222, 1988.
19. TURNER, N.A., MOAKE, J.L., KAMAT, S.G., SCHAFER, A.I., KLEINMAN, N.S., JORDAN, R., Mcintire, L.V. Comparative real-time effects on platelet adhesion and aggregation under flowing condition of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 91, 1354-1362, 1995.
20. COLLER, B.S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 76, 101-108, 1985.
21. MAZOYER, E., CAEN, J.P., TENZA, D., CRAMER, E.M. The anti-aggregating peptide KRDS impairs α-granule release, whereas RGDS does not. Platelets 6, 91-98, 1995.
22. CHALUPOWICZ, D.G., CHOWDHURY, Z.A., BACH, T.L., BARSIGIAN, C., MARTINEZ, J. Fibrin II induces endothelial cell capillary tube formation. J Cell Biol 130, 207-215, 1995.
23. CHANG, M., WANG, B., HUANG, T. Characterization of endothelial cell differential attachment to fibrin and fibrinogen and its inhibition by arg-gly-asp-containing peptides. Thromb Haemost 74, 764-769, 1995.
24. MOUSA, S.A., DEGRADO, W.F., MU, D., KAPIL, R.P., LUCCHESI, B.R., REILLY, T.M. Oral antiplatelet, antithrombotic efficacy of DMP728, a novel platelet GPIIb/IIIa antagonist. Circulation 93, 537-543, 1996.